India, June 4 -- Merus N.V. (MRUS), a Dutch oncology company developing multispecific antibodies and antibody drug conjugates, Wednesday announced the pricing of an underwritten public offering of around 5.26 million shares, at a price of $57.00 per share. The gross proceeds from the offering are expected to be around $300 million.
The net proceeds from the offering, together with its existing cash, cash equivalents and marketable securities, will be used to advance the clinical development of its product candidates, as well as for preclinical research and technology development, among others.
Merus also granted the underwriters a 30-day option to purchase up to an additional 789,473 shares.
The expected gross proceeds is before deductin...